Thoracic Surgery - Clinical trials - Mayo Clinic

COVID-19 Advice updates and vaccine options

Find out about COVID-19, COVID-19 vaccines, and Mayo Clinic patient and visitor updates. Skip to site navigation Skip to Content This content does not have an English version.This content does not have an Arabic version. Search Request an Appointment Find a Doctor Find a Job Give Now Log in to Patient Account English Español العربية 简体中文 Twitter Facebook Pinterest YouTube Menu Request an Appointment Departments & Centers Medical Departments & Centers

Thoracic Surgery

Clinical trials

Below are current clinical trials.
25 studies in Thoracic Surgery
(open studies only). Filter this list of studies by location, status and more.

BT – L-CsA – 301 – SLT A Phase III Prospective Multicenter Randomized Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A L-CsA Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Syndrome Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation

Jacksonville, Fla. The purpose of this study is to analyze L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with Bronchiolitis Obliterans Syndrome (BOS) following single-lung transplant. Patients will receive either L-CsA (5 mg) via the PARI Investigational eFlow Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA following completion of BOSTON-1.

An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed participation to BOSTON-1 and BOSTON-2 studies

Jacksonville, Fla. The purpose of this study is to assess the long-term effectiveness and safety of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients. Enrollment will be limited to patients who have completed 48 weeks participation in either the BT-L-CsA-301-SLT (BOSTON-1) or BT-L-CsA-302-DLT (BOSTON-2) trial. All patients in this clinical trial will receive L-CsA in addition to Standard of Care, regardless of randomization arm in prior trials.

Three-Dimensional Printing in Planning Thoracic Surgical Procedures

Rochester, Minn. The purpose of this study is to examine the utility of 3-D printing at a single institution.

Surveillance HeartCare Outcomes Registry

Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.

Mayo Clinic Upper Digestive Disease Survey

Rochester, Minn. The Mayo Clinic Upper Digestive Disease Survey has been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires/survey. Data will also lead to the establishment of “normal” or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.

Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now

Rochester, Minn. REVOLUTION will be a US multicenter observational registry in scope and governed by a steering committee of approximately 8 experts in NSCLC and outcomes research. The primary goal of the registry is characterizing patterns of use for NSCLC therapy. REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to examine primary questions of interest in the EGFR mutant population. Patients will be enrolled over a three year period across approximately 25 geographically diverse academic as well as community based sites within the US. The five year follow-up period will ensure robust survival data for correlations with clinical, tumor, and treatment variables. The target of 2,500 patients is meant to ensure adequate numbers of NSCLC patients with particular characteristics of interest including patients with adenocarcinoma, and EGFR mutations and effectively evaluate these patients with respect to key outcomes of interest including overall survival, time to progression, stage at progression, secondary metastases including brain metastases (at diagnosis and progression), comorbidity burden, and performance status at index date. The study design allows a cross-sectional perspective with collection of detailed patient and clinical characteristics at enrollment followed by longitudinal assessment of clinician and patient-reported endpoints every three months. Centralized follow-up will be conducted by having sites upload patient data following each visit via the web-based data system, with patients who do not show up for site visits being contacted via telephone by the Duke Clinical Research Institute (DCRI) call center. Site recruitment and patient enrollment will be weighted based upon provider specialty and ability to enroll patients with NSCLC with the specified inclusion criteria.

LS1681 A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Rochester, Minn. This phase I trial studies the best dose and side effects of AR160 in treating patients with B-cell non-Hodgkin lymphoma that has come back or is not responding to treatment. AR160 is a combination of paclitaxel albumin-stabilized nanoparticle formulation and rituximab. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma.

Effect of TTFields 150 kHz in Non-small Cell Lung Cancer NSCLC Patients With 1-10 Brain Metastases Following Radiosurgery METIS

Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

A Study to Collect Thoracic Specimens to Develop a Thoracic Specimen Registry

Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.

A Study of Performing Surgery for Resectable Malignant Pleural Mesothelioma After Radiation Therapy

Rochester, Minn. The purpose of this study is to assess the possibility, safety, and therapeutic effect of administering a short, quick course of high-dose radiation treatment focused on half of the chest, followed by surgery to remove that portion of the lungs, in patients with malignant pleural mesothelioma. Request an Appointment at Mayo Clinic Locations, travel & lodgingResearch Sept. 24, 2022 Share on: FacebookTwitter